Earnings Call · Q4 FY2022·2023-03-06

Q4 22EPS +4.00%·Rev n/aQ3 22EPS -42.86%·Rev n/aQ2 22EPS -16.67%·Rev n/aQ1 22EPS -13.64%·Rev n/a⚠ consensus missing

OCULAR THERAPEUTIX, INC OCUL

Donald Notman — Chief Financial Officer

Antony Mattessich — Chief Executive Officer

Steve Meyers — Vice President, Sales

Rabia Ozden — Head of R&D or similar role in clinical development

+16.4%1d on move date+14.1% vs SPY3d+16.7%5d+22.1%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more OCUL calls or request research access.

More OCUL calls Browse calls Request research access